Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Assets (2016 - 2025)

Historic Current Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $204.3 million.

  • Enanta Pharmaceuticals' Current Assets fell 3185.44% to $204.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year decrease of 3185.44%. This contributed to the annual value of $204.3 million for FY2025, which is 3185.44% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Current Assets stood at $204.3 million, which was down 3185.44% from $222.7 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Current Assets peaked at $448.5 million during Q2 2023, and registered a low of $204.3 million during Q3 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Current Assets averaged around $318.6 million, with its median value being $313.0 million (2022).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Current Assets skyrocketed by 4326.35% in 2023 and then crashed by 3609.67% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Current Assets (Quarter) stood at $327.0 million in 2021, then decreased by 13.23% to $283.7 million in 2022, then surged by 37.57% to $390.3 million in 2023, then plummeted by 31.3% to $268.1 million in 2024, then fell by 23.8% to $204.3 million in 2025.
  • Its last three reported values are $204.3 million in Q3 2025, $222.7 million for Q2 2025, and $242.9 million during Q1 2025.